BMO Capital Starts Coherus Biosciences (CHRS) at Outperform

BMO Capital initiates coverage on Coherus Biosciences (NASDAQ: CHRS) with a Outperform rating and a price target of $54.00.

Analyst Ian Somaiya sees an attractive entry point as the current price appears to reflect a delay to the FDA approval of CHS-1710. The analyst believes that a "likely on-time approval of CHS-1701 could enable CHRS shares to rapidly approach our price target". The analyst expects CHS-1701 to be approved by June 9.

For an analyst ratings summary and ratings history on Coherus Biosciences click here. For more ratings news on Coherus Biosciences click here.

Shares of Coherus Biosciences closed at $19.30 yesterday.

You May Also Be Interested In

• BMO Capital Starts Amapa Minerals Holdings (AMAP:CN) at Outperform
• RBC Capital Starts Cencora Inc (COR) at Sector Perform
• Nomura/Instinet Starts Unitree Robotics (688836:CH) at Buy